Shanghai Sanyou Medical Co., Ltd, established in 2005, is a corporation devoted to the R&D, manufacture and sales of independently innovative orthopedics products. The main products of Shanghai Sanyou are spinal and trauma implants. Shanghai Sanyou is one of the few companies that possess the ability to make original innovations based on clinical requirements in the field of spinal implants in China. The stock symbol of Sanyou Medical is 688085.
Since the establishment of Shanghai Sanyou Medical, we highly emphasize the upgrading of products. Leading by Dr. Michael Mingyan Liu, Chairman and Chief Scientist of Shanghai Sanyou Medical, our company has set up a comprehensive product development system and has the most advanced R&D equipment and project management system to ensure the advance, effective and reliability of product. By the end of January 2021, we have received 22 Class III medical device registration certificates and 131 patents, including 28 China invention patents, 98 China utility model patents, 1 USA utility patent, 1 Australia invention patent, 1 Japan invention patent, 1 German utility model patent and 1 China design patent. Our company and products have received a lot of prizes and honors, such as the first prize of Science Progress Award of Science Research Famous Achievement Award in Higher Institution, the second prize of China Medical Science and Technology Award, Pilot Enterprise of Patent Work in Shanghai, Famous and High Quality Medical Device Products in Shanghai, Shanghai Science and Technology Small Giant Enterprise and so on.
In the future, we will increase the R&D investment continuously and remain our lead in the field of spinal implants in China based on the industrial policy to encourage innovation of domestic medical device products via the opportunity of being listed on the Science and Technology Innovation Board. We strive for a significant increase in market share. We will enrich and improve orthopedic product series further and enhance the value of our company to realize the continuous, healthy and rapid development of our company and maximize the interests of investors.